Nektar Therapeutics last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $10.1 million (-9.3% year over year) and diluted EPS of -$1.23. It usually reports 37–71 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–71 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
10
-9.3%
|
-41
+2.3%
|
-1.23
+58.3%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
11
+3.8%
|
-45
+11.7%
|
-1.82
+49.7%
|
|
Mar 12, 2026
71 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
22
-25.3%
|
-36
-596.9%
|
-1.78
-442.5%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
12
-51.1%
|
-36
+4.1%
|
-1.87
+29.7%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11
-52.4%
|
-42
+20.6%
|
-2.95
+21.5%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
10
-51.7%
|
-51
-38.3%
|
-3.62
-1805.3%
|
|
Mar 12, 2025
71 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
29
+22.1%
|
7
+117.3%
|
0.52
+335.8%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
24
-0.1%
|
-37
+19.2%
|
-2.66
-1008.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NKTR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 906709
- Former names
- INHALE THERAPEUTIC SYSTEMS INC (until Jan 10, 2003); INHALE THERAPEUTIC SYSTEMS (until May 14, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.